Kintara completes reverse merger with TuHURA; renamed TuHURA Biosciences, trades as HURA

TuHURA Biosciences, Inc./NV

Merger closed Oct 18, 2024; Kintara securityholders own ~2.85% of combined entity (or 5.45% if CVR milestone met).
TuHURA securityholders own ~97.15% (or 94.55% after CVR shares).
1-for-35 reverse stock split pre-merger; common stock now trades under HURA on Nasdaq.
CVRs issued to former Kintara holders; up to ~1.54M shares payable if REM-001 CMBC study milestone met by Dec 31, 2025.
Combined company focuses on TuHURA's personalized cancer vaccine IFx-2.0; Phase 3 trial in MCC planned for Q1 2025.

item 2.01 item 1.01 item 9.01 item 5.02 item 2.02 item 3.03 item 5.01 item 5.03 item 5.06 item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.